A growing list of de-SPACs have gone bankrupt, adding further pressure to the beleaguered blank check space. Year-to-date, five companies that went public via SPAC merger have filed for bankruptcy, matching the full-year total from 2022 with more than eight...read more
An insurance platform and a medical device company went public this past week, both of which upsized their deals and priced above the range. Two SPACs also went public. The IPO market is continuing to open up, and an uptick in filings is setting the stage for a...read more
Longview Acquisition, a blank check company formed by executives at healthcare-focused hedge fund Glenview Capital, raised $360 million by offering 36 million shares at $10, the low end of the range of $10 to $10. Longview Acquisition plans to list on the NYSE...read more
Lyra Therapeutics (LYRA) popped 16% in its IPO this past week, the latest biotech to surge in its public debut. It was joined by three SPACs, continuing an uptick in blank check activity. Despite enduring ...read more
Five SPAC mergers have gone bankrupt this year, tying 2022
A growing list of de-SPACs have gone bankrupt, adding further pressure to the beleaguered blank check space. Year-to-date, five companies that went public via SPAC merger have filed for bankruptcy, matching the full-year total from 2022 with more than eight...read more
US IPO Weekly Recap: The IPO market picks up before Memorial Day
An insurance platform and a medical device company went public this past week, both of which upsized their deals and priced above the range. Two SPACs also went public. The IPO market is continuing to open up, and an uptick in filings is setting the stage for a...read more
Glenview Capital's SPAC Longview Acquisition prices upsized $360 million IPO at $10
Longview Acquisition, a blank check company formed by executives at healthcare-focused hedge fund Glenview Capital, raised $360 million by offering 36 million shares at $10, the low end of the range of $10 to $10. Longview Acquisition plans to list on the NYSE...read more
US IPO Weekly Recap: Biotech hot streak continues amid another wave of SPACs
Lyra Therapeutics (LYRA) popped 16% in its IPO this past week, the latest biotech to surge in its public debut. It was joined by three SPACs, continuing an uptick in blank check activity. Despite enduring ...read more